Seven Fleet Capital Management LP Buys 91,958 Shares of Roivant Sciences Ltd. $ROIV

Seven Fleet Capital Management LP boosted its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 71.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 220,126 shares of the company’s stock after buying an additional 91,958 shares during the quarter. Roivant Sciences makes up 1.3% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its 17th largest holding. Seven Fleet Capital Management LP’s holdings in Roivant Sciences were worth $7,790,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of ROIV. Goldman Sachs Group Inc. grew its stake in shares of Roivant Sciences by 15.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock worth $24,553,000 after acquiring an additional 324,764 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Roivant Sciences by 1.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock valued at $24,678,000 after purchasing an additional 34,341 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Roivant Sciences by 1.9% during the second quarter. American Century Companies Inc. now owns 89,625 shares of the company’s stock valued at $1,010,000 after purchasing an additional 1,689 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of Roivant Sciences by 149.9% during the second quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock valued at $129,000 after purchasing an additional 6,879 shares in the last quarter. Finally, M&T Bank Corp boosted its holdings in Roivant Sciences by 10.2% during the second quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock worth $144,000 after purchasing an additional 1,181 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on ROIV shares. Leerink Partners set a $42.00 price objective on shares of Roivant Sciences in a research report on Thursday, May 21st. Citigroup lifted their target price on shares of Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Sanford C. Bernstein upgraded Roivant Sciences to a “strong-buy” rating in a research note on Wednesday, July 29th. Guggenheim upped their target price on Roivant Sciences from $36.00 to $42.00 and gave the company a “buy” rating in a report on Friday, August 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Roivant Sciences in a research report on Wednesday, August 19th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $35.14.

Roivant Sciences Price Performance

NASDAQ ROIV opened at $36.75 on Thursday. The business’s fifty day moving average is $34.97 and its 200-day moving average is $30.80. The stock has a market capitalization of $26.55 billion, a price-to-earnings ratio of -69.34 and a beta of 1.12. Roivant Sciences Ltd. has a one year low of $11.85 and a one year high of $37.97.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The company had revenue of $1.44 million during the quarter, compared to analyst estimates of $2.06 million. Research analysts expect that Roivant Sciences Ltd. will post -2 EPS for the current fiscal year.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, Director Melissa B. Epperly sold 17,750 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $34.38, for a total value of $610,245.00. Following the completion of the sale, the director directly owned 16,474 shares of the company’s stock, valued at $566,376.12. This trade represents a 51.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric Venker sold 200,000 shares of the stock in a transaction on Monday, July 27th. The stock was sold at an average price of $34.95, for a total value of $6,990,000.00. Following the transaction, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at $56,376,551.85. The trade was a 11.03% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 2,855,913 shares of company stock worth $100,107,258. Company insiders own 8.80% of the company’s stock.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.